Business Context and Reporting Period
Company: Nanophase Technologies Corporation (Note: Metadata listed "SOLESENCE, INC." but filing content confirms Nanophase Technologies Corporation).
Reporting Period: Quarterly period ended March 31, 2004 (Form 10-Q).
Business Overview: Nanophase is a developer and commercial manufacturer of nanocrystalline materials used in personal care (sunscreens), abrasion-resistant applications, environmental catalysts, and polishing applications (semiconductors, hard disk drives). The company operates in a single segment with all long-lived assets located in the United States.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Total Revenue | $1,293,359 | $1,664,082 |
| Net Loss | $(1,470,564) | $(1,436,717) |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.09) |
| Cash and Cash Equivalents | $607,704 | $356,191 |
| Total Investments | $14,163,741 | $4,562,364 |
| Total Current Assets | $16,949,180 | $7,573,844 |
| Total Current Liabilities | $2,520,510 | $2,260,063 |
| Long-Term Debt (less current) | $111,649 | $251,843 |
| Accumulated Deficit | $(47,207,639) | $(45,737,075) |
Cash Flow Summary: Net cash used in operating activities was $(418,855). Net cash used in investing activities was $(9,614,920), primarily due to purchases of held-to-maturity investments. Net cash provided by financing activities was $10,241,480, driven by a $10.0 million equity investment.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 22.3% to $1.29 million. Product revenue dropped 21.1% due to decreased sales of sunscreen materials to BASF and CMP materials to Rohm and Haas Electronic Materials (RHEM). Other revenue decreased 27.6%, largely due to the absence of a one-time equipment sale in the prior year.
- Liquidity Improvement: Cash, cash equivalents, and investments increased significantly from $4.96 million at year-end 2003 to $14.77 million at March 31, 2004. This was primarily due to a $10.0 million private placement equity investment from Altana Chemie AG on March 23, 2004.
- Expense Management: Cost of revenue decreased 21.6% to $1.21 million, tracking with lower revenue volume. Selling, general, and administrative (SG&A) expenses decreased slightly to $1.06 million due to lower legal and insurance fees, offset by higher salaries and audit fees.
- Debt Reduction: Long-term debt decreased by approximately $140,000 due to principal payments.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Management expects increased demand for sunscreen and personal care materials in 2004 compared to 2003.
- The company anticipates revenue growth in the chemical-mechanical-planarization (CMP) and fine polishing markets beginning in 2005.
- A joint development agreement with Altana Chemie AG was executed to explore new applications in paints, coatings, and plastics, with Altana expected to become a significant customer in 2005.
- The company expects to continue reducing product manufacturing costs but may or may not operate at a positive gross margin in 2004 depending on revenue volume.
Material Risks and Contingencies:
- Customer Concentration: Three customers (BASF, RHEM, and C.I. Kasei) accounted for approximately 94.4% of total revenue for the quarter. Loss of orders from these customers would materially harm operations.
- Supply Agreement Triggers: The supply agreement with BASF contains financial covenants. A "triggering event" (e.g., negative earnings combined with cash/investments under $2.0 million, or debt acceleration over $10 million) could force the company to transfer technology and sell production equipment to BASF at 115% of net book value. Management believes current cash balances ($14.8 million) avoid this trigger for the foreseeable future.
- Capital Needs: The company has an accumulated deficit of $47.2 million and expects to continue incurring losses through at least the end of 2004. Additional financing may be required, which could be dilutive.
- Patent Reexamination: The USPTO granted a request for reexamination of a key patent (No. 6,669,823 B1) related to the NanoArc Synthesis process. Narrowing of claims could impair legal protection.
Investor Verification Checklist
- Covenant Compliance: Verify that cash, cash equivalents, and investments remain above the $2.0 million threshold required to avoid the mandatory technology/equipment transfer to BASF.
- Customer Retention: Monitor order volumes from the top three customers (BASF, RHEM, C.I. Kasei), which represent the vast majority of revenue.
- Equity Dilution: Assess the impact of the $15 million universal shelf registration and potential warrant exercises on existing shareholder ownership.
- Patent Status: Track the outcome of the USPTO reexamination of Patent No. 6,669,823 B1 regarding the NanoArc Synthesis process.
- Altana Partnership: Evaluate the progress of the joint development agreement with Altana Chemie AG and its potential to generate revenue in 2005.